Nat Rev Drug DiscovJClub
Towards mRNA therapeutics 2.0.
Nature Reviews Drug Discovery · · Review
Chien, Foo + 1 more
Abstract ↗AI summary
The abstract is read at the publisher; the summary is JClub's.
mRNA therapeutics are poised for a “2.0” era as clinical studies identify key barriers and emerging technical advances, including immune-silent formulations enabling repeated dosing.
- Why it matters: Despite rapid vaccine progress, translating mRNA into therapies for rare and common diseases depends on overcoming delivery, immunogenicity, and targeting challenges.
- What they did: The review synthesizes insights from selected clinical studies spanning enzyme replacement for rare disorders, cancer immunotherapies, genome-modifying treatments, and immune cell reprogramming, highlighting in vivo delivery and formulation strategies.
- The result: Clinically tractable delivery, immune-silent mRNA-vehicle formulations for repeated administration, and preferential delivery beyond the liver are expected to expedite development of mRNA therapeutics 2.0.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.
Free. We’ll email you when a new paper cites this one or any other paper you follow on JClub — at most one email a day. Every email has a one-tap unsubscribe.